LawPlayer
My bookmarks
Source

Commission Delegated Regulation (EU) 2025/1222 of 2 April 2025 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council as regards the harmonised classification and labelling of certain substances

Commission Delegated Regulation (EU) 2025/1222 of 2 April 2025 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council as regards the harmonised classification and labelling of certain substances

Delegated Regulation (EU) 2025/1222 · Regulation · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

Article 2

Open ↗

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union . It shall apply from 1 February 2027. However, suppliers may classify, label and package substances and mixtures in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation from the date of entry into force of this Regulation.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX Part 3, Table 3, of Annex VI to Regulation (EC) No 1272/2008 is amended as follows: (1) the following entries are inserted following the consecutive order of the index numbers corresponding to each entry: Index No Chemical Name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATEs Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘607-776-00-5 2-ethylhexanoic acid, monoester with propane-1,2-diol 285-503-5 85114-00-7 Repr. 1B H360D GHS08 Dgr H360D’       ‘612-300-00-4 N -1-naphthylaniline; N -phenylnaphthalen-1-amine 201-983-0 90-30-2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 H302 H373 (blood system, liver) H317 GHS07 GHS08 Wng   H302 H373 (blood system, liver) H317   oral: ATE = 1 200  mg/kg bw’   ‘026-005-00-8 tetrairon tris(pyrophosphate); ferric pyrophosphate 233-190-0 10058-44-3 Eye Irrit. 2 H319 GHS07 Wng H319’       ‘604-103-00-7 α,α’-propylenedinitrilodi- o -cresol 202-374-2 94-91-7 Repr. 1B H360FD GHS08 Dgr H360FD’       ‘008-004-00-4 ozone 233-069-2 10028-15-6 Ox. Gas 1 Carc. 2 Muta. 2 Acute Tox. 1 STOT SE 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H270 H351 H341 H330 H370 (nervous system, respiratory system, cardiovascular system) H372 (nervous system, respiratory system) H400 H410 GHS03 GHS08 GHS06 GHS09 Dgr H270 H351 H341 H330 H370 (nervous system, respiratory system, cardiovascular system) H372 (nervous system, respiratory system) H410   inhalation: ATE = 10 ppmV STOT SE 1; H370: C ≥ 0,002 % STOT SE 2; H371: 0,0005 % ≤ C < 0,002 % STOT RE 1; H372: C ≥ 0,05 % STOT RE 2; H373: 0,01 % ≤ C < 0,05 % M = 100 M = 1’   ‘007-031-00-9 dinitrogen oxide 233-032-0 10024-97-2 Repr. 1B STOT SE 3 STOT RE 1 Ozone 1 H360Df H336 H372 (nervous system) H420 GHS08 GHS07 Dgr H360Df H336 H372 (nervous system) H420’       ‘056-006-00-9 barium chromate 233-660-5 10294-40-3 Carc. 1B H350 GHS08 Dgr H350’       ‘650-060-00-2 Chrysanthemum cinerariaefolium , extract from open and mature flowers of Tanacetum cinerariifolium obtained with supercritical CO 2 289-699-3 89997-63-7 Acute Tox. 4 Acute Tox. 4 STOT SE 1 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H332 H302 H370 (nervous system) H373 (respiratory tract, inhalation) H317 H400 H410 GHS07 GHS08 Dgr H332 H302 H370 (nervous system) H373 (respiratory tract, inhalation) H317 H410   inhalation: ATE = 2,6 mg/L (dusts or mists) oral: ATE = 730 mg/kg bw M = 1 000 M = 100’   ‘650-059-00-7 Chrysanthemum cinerariaefolium , extract from open and mature flowers of Tanacetum cinerariifolium obtained with hydrocarbon solvents 289-699-3 89997-63-7 Acute Tox. 4 Acute Tox. 4 STOT SE 1 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H332 H302 H370 (nervous system) H373 (respiratory tract, inhalation) H317 H400 H410 GHS07 GHS08 Dgr H332 H302 H370 (nervous system) H373 (respiratory tract, inhalation) H317 H410   inhalation: ATE = 2,6 mg/L (dusts or mists) oral: ATE = 730 mg/kg bw M = 1 000 M = 100’   ‘607-777-00-0 barium bis[2-chloro-5-[(2-hydroxy-1-naphthyl)azo]toluene-4-sulphonate]; C.I. Pigment Red 53:1 225-935-3 5160-02-1 Carc. 2 H351 GHS08 Wng H351’       ‘608-070-00-X 2-bromo-2-(bromomethyl)pentanedinitrile; [DBDCB] 252-681-0 35691-65-7 Acute Tox. 2 Acute Tox. 4 STOT RE 2 Eye Dam. 1 Skin Sens. 1A Aquatic Chronic 2 H330 H302 H373 (thyroid, central nervous system) H318 H317 H411 GHS06 GHS08 GHS05 GHS09 Dgr H330 H302 H373 (thyroid, central nervous system) H318 H317 H411   inhalation: ATE = 0,27 mg/L (dusts or mists) oral: ATE = 500 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,001 %’   ‘607-779-00-1 9-octadecenoic acid (Z)-, sulfonated, potassium salts [1]; Reaction products of fatty acids, C18 (unsaturated) alkyl with sulfur trioxide, potassium salts [2]; 9(or 10)-sulphooctadecanoic acid, potassium salt [3] 271-843-1 [1]; - [2]; 267-966-5 [3] 68609-93-8 [1]; - [2]; 67968-63-2 [3] Repr. 1B H360D GHS08 Dgr H360D’       ‘613-352-00-0 bixlozone (ISO); 2-(2,4-dichlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one — 81777-95-9 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410   M = 1 M = 10’   ‘603-248-00-3 2,3-epoxypropyl isopropyl ether 223-672-9 4016-14-2 Repr. 1B H360F GHS08 Dgr H360F’       ‘607-778-00-6 tetrahydrofurfuryl methacrylate 219-529-5 2455-24-5 Repr. 1B Skin Sens. 1A H360Df H317 GHS08 GHS07 Dgr H360Df H317’       ‘015-209-00-2 trimethyl phosphate 208-144-8 512-56-1 Carc. 1B Muta. 1B Repr. 1B Acute Tox. 4 STOT RE 2 H350 H340 H360FD H302 H373 (nervous system) GHS08 GHS07 Dgr H350 H340 H360FD H302 H373 (nervous system)   oral: ATE = 1 300  mg/kg bw’   ‘602-111-00-5 fluoroethylene 200-832-6 75-02-5 Carc. 1A Muta. 2 H350 H341 GHS08 Dgr H350 H341     D’ ‘602-112-00-0 2-bromo-3,3,3-trifluoroprop-1-ene — 1514-82-5 Repr. 1B STOT SE 3 STOT SE 3 H360FD H335 H336 GHS08 GHS07 Dgr H360FD H335 H336’       ‘613-353-00-6 2-methyl-2 H -isothiazol-3-one hydrochloride; 2-methyl-2,3-dihydro-1,2-thiazol-3-one hydrochloride 247-499-3 26172-54-3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Acute Aquatic 1 Acute Chronic 1 H330 H311 H301 H314 H318 H317 H400 H410 GHS06 GHS05 GHS09 Dgr H330 H311 H301 H314 H317 H410 EUH071 inhalation: ATE = 0,15 mg/L (dusts or mists) dermal: ATE = 320 mg/kg bw oral: ATE = 180 mg/kg bw Skin. Sens 1A; H317: C ≥ 0,0015 % M = 10 M = 1’   ‘603-249-00-9 2,3-epoxypropyl o-tolyl ether 218-645-3 2210-79-9 Skin Irrit. 2 Skin Sens. 1A Muta. 2 Aquatic Chronic 2 H315 H317 H341 H411 GHS07 GHS08 GHS09 Wng H315 H317 H341 H411     C’ ‘607-780-00-7 methyl oct-2-ynoate 203-836-6 111-12-6 Skin Sens. 1A H317 GHS07 Wng H317’       ‘612-301-00-X dinotefuran (ISO); ( RS )-1-methyl-2-nitro-3-(tetrahydro-3-furylmethyl)guanidine - 165252-70-0 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H302 H400 H410 GHS07 GHS09 Wng H302 H410   oral: ATE = 2 000  mg/kg bw M = 10 M = 10’   (2) the entries corresponding to index numbers 015-012-00-1, 601-027-00-6, 602-025-00-8, 607-231-00-1, 613-044-00-6, 613-045-00-1, 615-008-00-5, 616-145-00-3, 616-211-00-1, 616-212-00-7 are replaced by the following entries respectively: Index No Chemical Name EC No CAS No Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) Specific Conc. Limits, M-factors and ATEs Notes ‘601-027-00-6 2-phenylpropene; α-methylstyrene 202-705-0 98-83-9 Flam. Liq. 3 Carc. 2 STOT SE 3 Eye Irrit. 2 Skin Sens. 1B Aquatic Chronic 2 H226 H351 H335 H319 H317 H411 GHS02 GHS08 GHS07 GHS09 Wng H226 H351 H335 H319 H317 H411   STOT SE 3; H335: C ≥ 25 % D’ ‘616-145-00-3 pethoxamid (ISO); 2-chloro- N -(2-ethoxyethyl)- N -(2-methyl-1-phenylprop-1-enyl)acetamide - 106700-29-2 Acute Tox. 4 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H302 H317 H400 H410 GHS07 GHS09 Wng H302 H317 H410   oral: ATE = 980 mg/kg bw M = 100 M = 10’   ‘015-012-00-1 tetraphosphorus trisulphide; phosphorus sesquisulphid 215-245-0 1314-85-8 Flam. Sol. 1 Self-heat. 1 Acute Tox. 4* H228 H251 H302 GHS02 GHS07 Dgr H228 H251 H302     T’ ‘602-025-00-8 1,1-dichloroethylene; vinylidene chloride 200-864-0 75-35-4 Flam. Liq. 1 Carc. 1B Muta. 2 Acute Tox. 1 Acute Tox. 3 STOT RE 1 Aquatic Chronic 3 H224 H350 H341 H330 H301 H372 (respiratory tract, kidney, liver) H412 GHS02 GHS08 GHS06 Dgr H224 H350 H341 H330 H301 H372 (respiratory tract, kidney, liver) H412   inhalation: ATE = 0,5 mg/L (vapours) oral: ATE = 300 mg/kg bw D’ ‘615-008-00-5 3-isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate; isophorone di-isocyanate 223-861-6 4098-71-9 Acute Tox. 1 Skin Corr. 1 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1A Aquatic Chronic 2 H330 H314 H334 H317 H411 GHS06 GHS05 GHS08 GHS09 Dgr H330 H314 H318 H334 H317 H411 EUH071 inhalation: ATE = 0,03 mg/L (dusts or mists) Resp. Sens. 1; H334: C ≥ 0,5 % Skin Sens. 1A; H317: C ≥ 0,001 % 2’ ‘613-045-00-1 folpet (ISO); N -(trichloromethylthio)phthalimide 205-088-6 133-07-3 Carc. 2 Acute Tox. 2 STOT RE 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H351 H330 H372 (respiratory tract) H318 H317 H400 H410 GHS08 GHS06 GHS05 GHS09 Dgr H351 H330 H372 (respiratory tract) H318 H317 H410 EUH066 inhalation: ATE = 0,30 mg/L (dusts or mists) STOT RE 1: C ≥ 5 % STOT RE 2: 0,5 % ≤ C < 5 % Skin Sens. 1A; H317: C ≥ 0,001 % M = 10 M = 10’   ‘613-044-00-6 captan (ISO); 1,2,3,6-tetrahydro- N -(trichloromethylthio)phthalimide 205-087-0 133-06-2 Carc. 2 Repr. 2 Acute Tox. 2 STOT RE 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H351 H361f H330 H372 H318 H317 H400 H410 GHS08 GHS06 GHS05 GHS09 Dgr H351 H361f H330 H372 H318 H317 H410   inhalation: ATE = 0,22 mg/L (dusts or mists) Skin Sens. 1A; H317: C≥ 0,001 % M = 10 M = 10’   ‘607-231-00-1 clopyralid (ISO); 3,6-dichloropyridine-2-carboxylic acid 216-935-4 1702-17-6 Eye Dam. 1 Aquatic Chronic 1 H318 H410 GHS05 GHS09 Dgr H318 H410 EUH066 M = 10’   ‘616-211-00-1 proquinazid (ISO); 6-iodo-2-propoxy-3-propylquinazolin-4(3 H )-one — 189278-12-4 Carc. 2 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H372 (thyroid, liver) H400 H410 GHS08 GHS09 Dgr H351 H372 (thyroid, liver) H410   M = 1 M = 10’   ‘616-212-00-7 3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate 259-627-5 55406-53-6 Acute Tox. 2 Acute Tox. 4 STOT RE 1 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H330 H302 H372 (larynx) H318 H317 H400 H410 GHS06 GHS08 GHS05 GHS09 Dgr H330 H302 H372 (larynx) H318 H317 H410   inhalation: ATE = 0,17 mg/L (dusts or mists) M = 10 M = 10’

Other acts of the same type
Commission Regulation (EU) 2019/1561 of 17 September 2019 amending Annexes II and III to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for chlormequat in cultivated fungi (Text with EEA relevance.)Commission Implementing Regulation (EU) 2019/1744 of 17 September 2019 on technical specifications for electronic ship reporting in inland navigation and repealing Regulation (EU) No 164/2010Commission Regulation (EU) 2019/1559 of 16 September 2019 amending Annexes II and III to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for cyflufenamid, fenbuconazole, fluquinconazole and tembotrione in or on certain products (Text with EEA relevance.)Council Implementing Regulation (EU) 2019/1403 of 12 September 2019 implementing Regulation (EU) No 269/2014 concerning restrictive measures in respect of actions undermining or threatening the territorial integrity, sovereignty and independence of UkraineCommission Implementing Regulation (EU) 2019/1394 of 10 September 2019 amending and correcting Implementing Regulation (EU) 2015/2447 as regards certain rules on surveillance for release for free circulation and exit from the customs territory of the UnionCommission Implementing Regulation (EU) 2019/1391 of 6 September 2019 amending Regulation (EC) No 1218/1999 concerning the classification of certain goods in the Combined Nomenclature and repealing Implementing Regulation (EU) No 670/2013Commission Implementing Regulation (EU) 2019/1404 of 6 September 2019 concerning the classification of certain goods in the Combined NomenclatureCommission Implementing Regulation (EU) 2019/1382 of 2 September 2019 amending certain Regulations imposing anti-dumping or anti-subsidy measures on certain steel products subject to safeguard measuresCommission Delegated Regulation (EU) 2019/1867 of 28 August 2019 supplementing Regulation (EU) No 1303/2013 of the European Parliament and of the Council with regard to the establishment of flat-rate financingCommission Implementing Regulation (EU) 2019/1374 of 26 August 2019 reopening of the investigation following the judgment of 3 July 2019, in case C-644/17 Eurobolt, with regard to Council Implementing Regulation (EU) No 723/2011 of 18 July 2011 extending the definitive anti-dumping duty imposed by Regulation (EC) No 91/2009 on imports of certain iron or steel fasteners originating in the People's Republic of China to imports of certain iron or steel fasteners consigned from Malaysia, whether declared as originating in Malaysia or notCommission Implementing Regulation (EU) 2019/1375 of 26 August 2019 amending for the 305th time Council Regulation (EC) No 881/2002 imposing certain specific restrictive measures against certain persons and entities associated with the ISIL (Da'esh) and Al-Qaida organisationsCommission Implementing Regulation (EU) 2019/1353 of 20 August 2019 amending for the 304th time Council Regulation (EC) No 881/2002 imposing certain specific restrictive measures directed against certain persons and entities associated with the ISIL (Da'esh) and Al-Qaida organisations

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next